User profiles for Benedetta Conte
 | Benedetta ConteUniversity of Barcelona Verified email at recerca.clinic.cat Cited by 846 |
[HTML][HTML] Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
Novel antibody-drug conjugates against HER2 are showing high activity in HER2-negative
breast cancer (BC) with low HER2 expression (ie, 1+ or 2+ and lack of ERBB2 amplification). …
breast cancer (BC) with low HER2 expression (ie, 1+ or 2+ and lack of ERBB2 amplification). …
[HTML][HTML] Frequency and spectrum of PIK3CA somatic mutations in breast cancer
…, E Sanfeliu, F Schettini, B Conte… - Breast cancer …, 2020 - Springer
Purpose The therascreen PIK3CA mutation assay and the alpha-specific PI3K inhibitor alpelisib
are FDA-approved for identifying and treating patients with advanced PIK3CA-mutated (…
are FDA-approved for identifying and treating patients with advanced PIK3CA-mutated (…
[HTML][HTML] Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer
…, MV Dieci, J Cortes, A Llombart-Cussac, B Conte… - …, 2022 - thelancet.com
Background Both clinical and genomic data independently predict survival and treatment
response in early-stage HER2-positive breast cancer. Here we present the development and …
response in early-stage HER2-positive breast cancer. Here we present the development and …
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: a systematic review and meta-analysis
Background HER2-positive (HER2+) breast cancer (BC) comprises all the four PAM50
molecular subtypes. Among these, the HER2-Enriched (HER2-E) appear to be associated with …
molecular subtypes. Among these, the HER2-Enriched (HER2-E) appear to be associated with …
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation
…, B Adamo, A Musolino, F Miglietta, B Conte… - The Lancet …, 2020 - thelancet.com
Background In early-stage HER2-positive breast cancer, escalation or de-escalation of systemic
therapy is a controversial topic. As an aid to treatment decisions, we aimed to develop a …
therapy is a controversial topic. As an aid to treatment decisions, we aimed to develop a …
[HTML][HTML] Sex hormones and hormone therapy during COVID-19 pandemic: implications for patients with cancer
C Cattrini, M Bersanelli, MM Latocca, B Conte… - Cancers, 2020 - mdpi.com
The novel coronavirus disease 2019 (COVID-19) shows a wide spectrum of clinical presentations,
severity, and fatality rates. The reason older patients and males show increased risk …
severity, and fatality rates. The reason older patients and males show increased risk …
[HTML][HTML] Update on the management of breast cancer during pregnancy
Simple Summary The diagnosis of cancer during pregnancy represents a challenging
situation, leading to a complex management aimed at maximizing the curative approach to the …
situation, leading to a complex management aimed at maximizing the curative approach to the …
[HTML][HTML] Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta …
F Poggio, M Bruzzone, M Ceppi, B Conte, S Martel… - ESMO open, 2018 - Elsevier
Single-agent poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) have been approved
as the first targeted therapy available for patients with BRCA-mutated HER2-negative …
as the first targeted therapy available for patients with BRCA-mutated HER2-negative …
Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase …
…, A Abate, L Miglietta, C Ferreccio, MC Pescio, B Conte… - The Breast, 2018 - Elsevier
Background Despite the availability of different strategies for ovarian function and/or fertility
preservation in young breast cancer patients candidates for chemotherapy, limited data are …
preservation in young breast cancer patients candidates for chemotherapy, limited data are …
Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the end of the debate
Neoadjuvant chemotherapy is the recommended approach for patients with triple-negative
breast cancer (TNBC) with clinically node-positive and/or tumors> 1 cm. 1 The addition of a …
breast cancer (TNBC) with clinically node-positive and/or tumors> 1 cm. 1 The addition of a …